BIOASTER is proud to be part of ERA4TB (European Regimen Accelerator for #Tuberculosis) project, a public-private initiative devoted to accelerating the development of new treatment regimens for tuberculosis. The ERA4TB...
News Release ImmunoSep: EU research project releases new animated video on personalised immunotherapy in sepsis. ImmunoSep challenges the standard ‘one-size-fits-all’ treatment approach to sepsis, which currently consists of the prescription...
As a member of the FunHoMic Network, BIOASTER invites you to join to the final FunHoMic’s conference on April 5 and 6, 2023 about “The Fungus-Host-Microbiota interplay” that will take...
Keen on furthering your skills in vaccine development? 📢Open call for #TRANSVAC2 #training! FREE training from experts in the field! 💥 Three courses are open for applications: ✔M3 #Adjuvants and...
BIOASTER is pleased to announce that the B2B2B AMR Dx consortium has officially been recommended for funding (B2B2B AMR Dx: Bench, Bedside, Business, and Beyond: innovative solutions for AMR diagnostics)...
Call for a unique opportunity in antibiotic community! The GNA NOW consortium (EU project) is looking for a novel antibiotic compound to progress to a clinical candidate. To find out...
BIOASTER announces the kick off a new IMI project “GNA NOW” (Gram-Negative Antibacterials NOW), led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI),...
BIOASTER teams are currently in Utrecht for the kick-off meeting of the European project GNA-NOW, part of the AMR Accelerator Programme of IMI 2. We are proud to be part...
KICK OFF PROJECT IMI VALUE-DX BIOASTER teams are currently in Madrid for the kick-off meeting of the Value-Dx project. We are proud to be part of such a consortium, funded...
Accelerate VACCINE European research: BIOASTER reinforces its participation to TRANSVAC2 European Project. 4th TRANSVAC call : BIOASTER now offers 2 state-of-the-art technologies services free of charge for users : Next...
The European Commission announces the start of the TRANSVAC2 project, coordinated by the European Vaccines Initiative (EVI) in the context of the Horizon 2020 Program. This project will offer services...
By continuing browsing this website, you accept the use of cookies or other tracers for statistics of visits to optimize the functionality of the site, and or privacy policy. AcceptRejectRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
